Yomna Abu-Farsakh, MD
Internal Medicine · North Canton, OHNPI 1780146365
Payments from drug & device makers
Across 53 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$127
- Sobi, Inc$124
- Novartis$92
- Johnson & Johnson$84
- Boehringer Ingelheim$66
- Pharmaessentia USA Corporation$54
- plus $783 from 27 others
What the payments were for
- Food & beverage$1,15287%
- Education$17813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 3 | $127 |
| Sobi, Inc | 2 | $124 |
| Novartis | 5 | $92 |
| Johnson & Johnson | 3 | $84 |
| Boehringer Ingelheim | 2 | $66 |
| Pharmaessentia USA Corporation | 2 | $54 |
| AVEO Pharmaceuticals, Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| AbbVie | 2 | $44 |
| Bayer | 2 | $44 |
| Legend Biotech USA Inc. | 2 | $39 |
| Puma Biotechnology, Inc. | 2 | $38 |
| Nuvation Bio Inc. | 2 | $38 |
| Stemline Therapeutics Inc. | 2 | $34 |
| EMD Serono, Inc. | 1 | $31 |
| Coherus Oncology, Inc. | 1 | $30 |
| Incyte Corporation | 1 | $29 |
| Immunocore Limited | 1 | $26 |
| Genentech USA, Inc. | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| GSK | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Gilead | 1 | $23 |
| Pfizer | 1 | $23 |
| Merck | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Sanofi | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Sandoz | 1 | $17 |
How this compares
$1,330 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $71,446 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $58,594 |
| OzempicSemaglutide | 53 | $56,723 |
| JardianceEmpagliflozin | 44 | $42,758 |
| JanuviaSitagliptin Phosphate | 31 | $40,083 |
| TrulicityDulaglutide | 19 | $18,534 |
| XareltoRivaroxaban | 43 | $15,879 |
| MyrbetriqMirabegron | 19 | $8,284 |
| Atorvastatin Calcium | 342 | $3,139 |
| Potassium Chloride | 72 | $2,171 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,097 |
| Omeprazole | 138 | $2,020 |
| Gabapentin | 151 | $1,849 |
| Levothyroxine Sodium | 184 | $1,787 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 14 | $1,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23 | $71,44661 claims |
| GSKTrelegy Ellipta | $25 | $58,59479 claims |
| Boehringer IngelheimJardiance | $66 | $42,75844 claims |
| MerckJanuvia | $22 | $40,08331 claims |
| Johnson & JohnsonXarelto | $84 | $15,87943 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in North Canton
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.